CoChat

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 11 of the 22 sources its claims cite were checked for support.

Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury.

Open access
Osstyn, Sander, Rauwenhoff, Johanne, Handels, Ron, de Vugt, Marjolein E., Evers, Silvia, van Mastrigt, Ghislaine A. P. G., van Heugten, Caroline M. · 2025 · International Journal of Technology Assessment in Health Care

Abstract

INTRODUCTION: Following acquired brain injury (ABI), individuals often experience anxiety and/or depressive symptoms. BrainACT is an adapted form of Acceptance and Commitment Therapy (ACT) tailored to this target group. The current study is a trial-based health-economic evaluation comparing BrainACT to a psychoeducation and relaxation control treatment. METHODS: An economic evaluation from a societal perspective was conducted in the Netherlands alongside a multicenter randomized controlled two-armed parallel trial including 72 participants. A cost-utility and cost-effectiveness analysis was conducted where incremental costs, quality-adjusted life-years (QALYs), and anxiety/depression (Hospital Anxiety and Depression Scale (HADS) score) were collected and presented over a 1-year follow-up period. Bootstrapping, scenario, and subgroup analyses were performed to test the robustness of the results. RESULTS: The BrainACT arm reported non-significant lower total costs (incremental difference of €-4,881; bootstrap interval €-12,139 to €2,330) combined with significantly decreased anxiety/depression (HADS) (3.2; bootstrap intervals 0.7-5.7). However, the total QALYs were non-significantly lower (-0.008; bootstrap interval -0.060 to 0.042) for BrainACT. The probability of the intervention being cost-effective was 86 percent at a willingness-to-accept threshold of €50,000/QALY. The scenario and subgroup analyses confirmed the robustness of the results. CONCLUSION: BrainACT may be a more cost-effective alternative to a psychoeducation and relaxation intervention for anxiety and/or depressive symptoms following ABI. Despite limitations, BrainACT appears to be a promising addition to treatment options in the Netherlands. Further research is needed to validate these findings, and consideration should be given to implementing BrainACT in Dutch clinical settings with ongoing monitoring.

Overview

CoChat Summary

## TL;DR

This trial-based economic evaluation found that BrainACT, an adapted ACT program for people with anxiety and/or depressive symptoms after acquired brain injury, was likely more cost-effective than psychoeducation plus relaxation from a societal perspective over 1 year. It produced lower mean costs and significantly better HADS outcomes, but slightly lower QALYs.

## Key findings

  • In the base-case societal analysis, BrainACT had lower mean total costs by €4,881 (bootstrap interval €−12,139 to €2,330) and better anxiety/depression outcomes by 3.2 HADS points (bootstrap interval 0.7–5.7).
  • BrainACT had non-significantly lower QALYs of −0.008 (bootstrap interval −0.060 to 0.042).
  • The probability that BrainACT was cost-effective was 86% at a willingness-to-accept threshold of €50,000/QALY.
  • In outcome testing over 12 months, the active control arm had significantly higher HADS depression scores (p = 0.013) and HADS total scores (p = 0.031), while QALYs (p = 0.775) and HADS anxiety (p = 0.372) did not differ significantly.

## Methods

  • Conducted alongside a multicenter randomized controlled two-armed parallel trial in the Netherlands, using a societal perspective and a 1-year follow-up.
  • Included 72 participants with objectified TBI or stroke and anxiety/depressive symptoms; 36 were randomized to BrainACT and 36 to psychoeducation plus relaxation.
  • Main analyses used intention-to-treat, mixed models for incremental outcomes, and 1,000 bootstrap replications; missing data were addressed with multiple imputation.

## Limitations

  • The paper states the sample size was 72, below the target of 94, which may have reduced statistical power and made subgroup analyses harder to interpret.
  • It reports inconsistencies in productivity data and notes these were handled by truncation; the text says results were still robust when inconsistent records were excluded.
  • Follow-up was only 1 year, which the authors say may be too short to assess long-term cost-effectiveness.
  • The paper also notes that material and facility costs were not included in intervention costs due to limited database information; this is an evident limitation from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s0266462324004811

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. (a) Incremental cost-utility plane. (b) Incremental cost-effectiveness plane.
Figure 1. (a) Incremental cost-utility plane. (b) Incremental cost-effectiveness plane.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

3 Valid · 6 Not valid · 4 Not checked · 53 Own results and interpretations

23 more claims

Create a free account to see all 66 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Hakkaart, 2016, Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg
  2. Zwaap, 2015, Kosteneffectiviteit in de praktijk [Dutch]

Metadata

Authors
Osstyn, S., Rauwenhoff, J., Handels, R., de Vugt, M. E., Evers, S., van Mastrigt, G. A. P. G., & van Heugten, C. M.
Affiliations
  • Maastricht University (NL)
  • Norwegian University of Science and Technology (NO)
Venue
International Journal of Technology Assessment in Health Care
Published
2025
Volume
41
Issue
1
Pages
e10-e10
ISSN
  • 0266-4623 (ISSN-L)
  • 1471-6348
OpenAlex
W4407291766
Cited by
0
References
43
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • International Journal of Technology Assessment in Health Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
Funders
ZonMw (636310003)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
Keywords
acceptance and commitment therapy, acquired brain injury, anxiety, depressive symptoms, cost-effectiveness, cost-utility analysis, psychoeducation, relaxation training, quality-adjusted life years
MeSH terms
Adult, Anxiety, Brain Injuries, Cost-Benefit Analysis, Depression, Female, Humans, Male, Middle Aged, Netherlands, Quality-Adjusted Life Years, Acceptance and Commitment Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury. https://app.cochat.ai/papers/10.1017/s0266462324004811
The paper
Osstyn, S., Rauwenhoff, J., Handels, R., de Vugt, M. E., Evers, S., van Mastrigt, G. A. P. G., & van Heugten, C. M. (2025). Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462324004811

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.